modified RECIST criteria
Showing 1 - 25 of >10,000
Follow up After TACE by Elastography and Color Doppler.
Not yet recruiting
- Hepatocellular Carcinoma
- US
- (no location specified)
Oct 2, 2023
Efficacy of Targeted Therapy for NSCLC
Recruiting
- Evaluation
- +2 more
- RecistTM criteria
-
Chongqing, Chongqing, ChinaCancer Center, Dapping Hospital, Army Medical Center of PLA
Nov 15, 2023
HEAVEN CRITERIA vs Modified LEMON Score for Predicting Difficult
Recruiting
- Intubation; Difficult or Failed
- Intubation Complication
-
Thrissur, Kerala, IndiaJMMCRI
Jul 13, 2023
Nutritional Status on Oncologic and Operative Outcome in
Recruiting
- Retroperitoneal Sarcoma
- +5 more
- Measurement of body composition with computed tomography (CT)
- +5 more
-
Ljubljana, SloveniaInstitute of Oncology Ljubljana
Dec 2, 2022
Clinical Performance of Ceramic Vonlays Trial in Cairo (Vonlay Ceramic restorations, Onlay Ceramic restorations)
Recruiting
- Clinical Performance of Ceramic Vonlays
- Vonlay Ceramic restorations
- Onlay Ceramic restorations
-
Cairo, El Manial, EgyptFaculty of Dentistry, Cairo University, 11 El-Saraya St. El Mani
Nov 6, 2021
Chinese Version, Fibromyalgia, Diagnosis Trial in Beijing
Completed
- Chinese Version
- +3 more
-
Beijing, Beijing, ChinaGuang'anmen Hospital
Jan 24, 2022
Dental Restoration Failure Trial (Short fiber resin composite, Polyethylene ribbon fiber)
Not yet recruiting
- Dental Restoration Failure
- Short fiber resin composite
- Polyethylene ribbon fiber
- (no location specified)
May 14, 2022
Class V Dental Caries Trial (Modified USPHS criteria)
Not yet recruiting
- Class V Dental Caries
- Modified USPHS criteria
- (no location specified)
Jul 16, 2022
Dental Restoration Failure Trial in Giza (X-tra base & GrandioSO reinforced by Ribbond)
Active, not recruiting
- Dental Restoration Failure
- X-tra base & GrandioSO reinforced by Ribbond
-
Giza, EgyptFaculty of Dentistry, Cairo University
Jul 19, 2022
Liver Metastases Trial (Diffusing Alpha Radiation Emitters Therapy (DaRT))
Not yet recruiting
- Liver Metastases
- Diffusing Alpha Radiation Emitters Therapy (DaRT)
- (no location specified)
Apr 23, 2023
Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Tumors Trial (MK-5684, Dexamethasone, Fludrocortisone
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Prostatic Neoplasms
- MK-5684
- +6 more
- (no location specified)
Nov 21, 2023
Metastatic Hormone-Sensitive Prostate Cancer Trial in China (biological, drug, procedure, other)
Active, not recruiting
- Metastatic Hormone-Sensitive Prostate Cancer
- Pembrolizumab
- +3 more
-
Beijing, Beijing, China
- +23 more
Sep 30, 2022
Melanoma Trial in Worldwide (Talimogene Laherparepvec, Pembrolizumab, Placebo)
Terminated
- Melanoma
- Talimogene Laherparepvec
- +2 more
-
Birmingham, Alabama
- +160 more
Nov 10, 2022
NSCLC Patient in a Metastatic Stage Eligible for First-line Treatment With Immune Checkpoint Inhibitor Trial in Boulogne
Recruiting
- NSCLC Patient in a Metastatic Stage Eligible for First-line Treatment With Immune Checkpoint Inhibitor
- assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.
-
Boulogne Billancourt, France
- +2 more
Jul 12, 2021
Malignant Melanoma Trial in Worldwide (Pembrolizumab, Lenvatinib, Placebo for lenvatinib)
Active, not recruiting
- Malignant Melanoma
- Pembrolizumab
- +2 more
-
Los Angeles, California
- +118 more
Aug 22, 2022
Hepatocellular Carcinoma Trial in Worldwide (lenvatinib, pembrolizumab (200 mg))
Completed
- Hepatocellular Carcinoma
- lenvatinib
- pembrolizumab (200 mg)
-
San Francisco, California
- +25 more
Jan 13, 2023
Gastric Adenocarcinoma, Malignant Melanoma Trial in Seoul (AZD6738, Durvalumab)
Active, not recruiting
- Gastric Adenocarcinoma
- Malignant Melanoma
-
Seoul, Korea, Republic ofSamsung Medical Center
Jun 13, 2022
Colorectal Cancer Trial in China (TQB2618 injection, Penpulimab injection, Anlotinib HCl capsules)
Not yet recruiting
- Colorectal Cancer
- TQB2618 injection
- +2 more
-
Fuyang, Anhui, China
- +14 more
Aug 23, 2023
Metastatic Hormone-Sensitive Prostate Cancer Trial in Worldwide (biological, drug, procedure, other)
Active, not recruiting
- Metastatic Hormone-Sensitive Prostate Cancer
- Pembrolizumab
- +3 more
-
Anchorage, Alaska
- +212 more
Aug 18, 2022
Prostatic Tumors Trial in Worldwide (Pembrolizumab, Docetaxel, Prednisone)
Active, not recruiting
- Prostatic Neoplasms
- Pembrolizumab
- +4 more
-
Mobile, Alabama
- +214 more
Nov 24, 2022
Prostatic Tumors Trial in Worldwide (Pembrolizumab, Enzalutamide, Placebo)
Active, not recruiting
- Prostatic Neoplasms
- Pembrolizumab
- +2 more
-
Mobile, Alabama
- +257 more
Nov 22, 2022
qSOFA, SIRS, and EWS for In-hospital Mortality in Emergency
Recruiting
- Sepsis
- Septic Shock
- Measurement of qSOFA score
- +4 more
-
Ar Rifā', Southern Governorate, Bahrain
- +7 more
Dec 11, 2021
Resin Cement Trial in Cairo (Active bio Activa, Resin Cement)
Unknown status
- Resin Cement
- Active bio Activa
- Resin Cement
-
Cairo, EL Manial, EgyptCairo University
Jan 26, 2021
